JESSICA SCAMPONE: Open Payments
NPI 1326536418 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,837 in 72 payments from 20 companies in 2025. Trend: 2023 $942 · 2024 $1,497 · 2025 $1,837
Food & beverage: $1,747Education: $90
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $402 |
| AstraZeneca Pharmaceuticals LP | 15 | $301 |
| Insmed, Inc. | 7 | $160 |
| Regeneron Healthcare Solutions, Inc. | 3 | $145 |
| Grifols USA, LLC | 5 | $131 |
| Verona Pharma, Inc. | 7 | $114 |
| INTUITIVE SURGICAL, INC. | 1 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $67 |
| Axsome Therapeutics, Inc. | 2 | $63 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $53 |
Products named: NUCALA, DUPIXENT, Arikayce, Prolastin-C Liquid, AREXVY, FASENRA, Ohtuvayre, TEZSPIRE.
Industry payments across MD — which companies pay providers there.
